<?xml version="1.0" encoding="UTF-8" ?> 
<root> 
<content type="str">Saidal group will expand its activities in 2017, with the admission of some new production units including that of insulin bottles, APS reported citing director general of this public company, Yacine Tounsi. 
Saidal has entered into production two categories of projects: production units of generic drugs and specialized units. 
Regarding generics, three (03) units will be delivered before the end of the first half of 2017: that of Cherchell for dry forms with an annual capacity of 25 million sales-units, that of Zmirli (Al Harrash), also for dry forms (55 million sales-units), and that of Constantine for liquid forms (28 million sales-units) 
 
In the same regard, specialized units include human insulin production project in Constantine, in partnership with the Novonordisk group.</content> 
<sequenceId type="str">695203135671</sequenceId> 
<topics type="list"> 
<item type="dict"> 
<group type="str">Regional</group> 
<name type="str">Algeria news</name> 
</item> 
</topics> 
<estimatedPublishedDate type="str">2017-01-29T08:19:08Z</estimatedPublishedDate> 
<title type="str">Saidal: New production units to enter into operation in 2017</title> 
</root>